TEVA-FULVESTRANT INJECTION 50 MG
FULVESTRANT : 50 MG · DIN 02460130 · TEVA CANADA LIMITED
Health Canada status: MARKETED
What is TEVA-FULVESTRANT INJECTION?
TEVA-FULVESTRANT INJECTION 50 MG contains FULVESTRANT : 50 MG. It is listed in the Health Canada Drug Product Database under DIN 02460130, held by TEVA CANADA LIMITED, supplied as SOLUTION for INTRAMUSCULAR administration. Health Canada currently lists it as marketed, status dated 15-Jan-2019. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
Product details and regulatory record
| DIN | 02460130 |
|---|---|
| Brand name | TEVA-FULVESTRANT INJECTION |
| Generic / active ingredient | FULVESTRANT : 50 MG |
| Manufacturer | TEVA CANADA LIMITED |
| Strength | 50 MG |
| Dosage form | SOLUTION |
| Route of administration | INTRAMUSCULAR |
| Schedule | Prescription |
| ATC code | L02BA03 FULVESTRANT |
| AHFS class | 08:12.18 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 15-Jan-2019 |
What can be used instead?
Other Canadian products sharing ATC code L02BA03 FULVESTRANT. 6 of 12 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| FASLODEX | 50 MG | SOLUTION | ASTRAZENECA CANADA INC | MARKETED | DIN 02248624 |
| FULVESTRANT INJECTABLE | 50 MG | SOLUTION | JAMP PHARMA CORPORATION | MARKETED | DIN 02530635 |
| FULVESTRANT INJECTION | 250 MG / 5 ML | SOLUTION | STERIMAX INC | MARKETED | DIN 02558971 |
| FULVESTRANT INJECTION | 50 MG | SOLUTION | FORMATIVE PHARMA INC. | MARKETED | DIN 02536293 |
| FULVESTRANT INJECTION | 50 MG | SOLUTION | SANDOZ CANADA INCORPORATED | MARKETED | DIN 02483610 |
| ACT FULVESTRANT | 50 MG | SOLUTION | ACTAVIS PHARMA COMPANY | CANCELLED PRE MARKET | DIN 02463075 |
| APO-FULVESTRANT | 50 MG | SOLUTION | APOTEX INC | APPROVED | DIN 02486350 |
| FULVESTRANT INJECTION | 50 MG | SOLUTION | MYLAN PHARMACEUTICALS ULC | CANCELLED POST MARKET | DIN 02468549 |
| FULVESTRANT INJECTION | 50 MG | SOLUTION | AURO PHARMA INC | APPROVED | DIN 02533111 |
| FULVESTRANT INJECTION | 50 MG | SOLUTION | ACCORD HEALTHCARE INC | CANCELLED POST MARKET | DIN 02486792 |
Who else supplies FULVESTRANT worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. FULVESTRANT appears in 105 registered pack listings across 13 markets, published on 11 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.